Leerink Partners Downgrades AbCellera Biologics (ABCL) to Market Perform
Tweet
Share
E-mail
Get Alerts ABCL Hot Sheet
Price: $11.38 +3.74%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Partners analyst Faisal Khurshid downgraded AbCellera Biologics (NASDAQ: ABCL) from Outperform to Market Perform with a price target of $4.00.
For an analyst ratings summary and ratings history on AbCellera Biologics click here. For more ratings news on AbCellera Biologics click here.
Shares of AbCellera Biologics closed at $4.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stripe, Advent In Talks To Buy Paypal - WSJ
- Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
- Full Circle Lithium closes $5.14M private placement
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
